Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02110784
Other study ID # ST3073-ST3074-DM13-001
Secondary ID 2013-003763-56
Status Terminated
Phase Phase 2
First received
Last updated
Start date June 18, 2014
Est. completion date April 30, 2017

Study information

Verified date June 2017
Source Alfasigma S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to investigate the efficacy, safety and tolerability of a therapeutic course of Eurartesim® in travellers who contracted malaria due to infection by P. vivax in endemic countries.


Description:

Vivax malaria occurs throughout the tropical, subtropical and some of the temperate latitudes globally. During a primary infection some P. vivax parasites become dormant in the liver (hypnozoites) during large periods of time and might subsequently cause multiple blood-stage relapses.

The asexual stages of P. vivax are generally still sensitive to chloroquine (CQ) throughout most of the world with the exception of Indonesia and Papua New Guinea where high therapeutic failure rates ranging from 5-84% have been reported. Also, there are reports of chloroquine failure from other countries and regions where the species is endemic; in particular, the presence of CQ-resistant vivax strains is now well described in several countries, including India, Brazil, Peru and Colombia.

The treatment of the dormant stages and the prevention of relapses is reached throughout the 8-aminoquinolines (primaquine is the only commercially available in this indication).

The current treatments recommended by World Health Organization (WHO) for the radical cure of CQ-resistant vivax malaria are Artemisinin based Combination Therapies (ACTs) with partner drugs having very long half-life, combined with a two weeks regiment of primaquine (WHO, 2010).

Among a variety of suitable artemisinin-based combinations, the fixed combination of dihydroartemisinin (DHA) and piperaquine (PQP )is considered an excellent therapeutic approach since it has got all the requirements considered essential for showing a positive benefit/risk ratio in malaria therapy.

Sigma-Tau i.f.r. S.p.A. has developed a DHA+PQP formulation (Eurartesim®) manufactured according to international Good Manufacturing Practice (GMP) standards and has recently received marketing authorization in Europe via a centralized procedure by the European Medicine Agency (EMA) for uncomplicated episodes of P. falciparum malaria.

A substantial amount of data have been collected in patients with uncomplicated P. falciparum malaria treated with the DHA+PQP combination. In addition, several studies have provided evidence of high cure rate in patients with P. vivax malaria treated with DHA+PQP, however, no data are available so far on efficacy and safety of the DHA+PQP treatment in patients with imported P. vivax malaria. Acquiring data is therefore of particular importance since malaria represents an important burden among all travel-acquired illnesses considering not only the number of cases (10-20% of the imported malaria cases are due to P. vivax infection) but also the potential of a fatal outcome.

The aim of the present study is to investigate the efficacy, safety and tolerability of a therapeutic course of Eurartesim® in travellers who contracted malaria due to infection by P. vivax in endemic countries. The results of such "proof of concept" study will be used for estimating the failure rate in a precise way and to dimension one or more subsequent phase III trials of comparative efficacy.


Recruitment information / eligibility

Status Terminated
Enrollment 27
Est. completion date April 30, 2017
Est. primary completion date November 23, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Have read the Information for the Patient and signed the Informed Consent Form;

- Aged =18 years and able to swallow oral medication;

- Body weight comprised between 24 kg and 100 kg (included) for males and females;

- Uncomplicated malaria with microscopically confirmed monoinfection by Plasmodium vivax or mixed infection (i.e. infection with P. vivax and other Plasmodium species);

- Willingness to comply with the study protocol and the study visit schedule.

Exclusion Criteria:

- Participation in any investigational drug study during the previous 30 days;

- Antimalarial treatment with chloroquine and quinine within the previous 6 weeks, with piperaquine-based compounds or mefloquine or lumefantrine within the previous 3 months and with halofantrine within the previous 30 days prior to screening;

- P. vivax/Plasmodium species asexual stage parasitaemia = 5% Red Blood Cells (in cases of mixed infection);

- Clinical and/or laboratory features of severe malaria according to WHO criteria (WHO 2010);

- ECG abnormality that requires urgent management (i.e. clinically significant arrhythmias, Atrio-Ventricular block II and III degree etc.);

- Family history of sudden death, or known congenital prolongation of the QT interval

- Lengthening of QT interval on ECG: corrected QT interval (Fridericia's correction) =450 ms for males and =470 ms for females;

- Concomitant administration of any treatment which can induce a lengthening of QT interval (i.e. antihistamines, macrolides, etc.) and of any antimalarial drugs (for the full list of prohibited drugs refer to section 8.3);

- Any contraindication to blood sampling (i.e. important haemorrhagic diathesis);;

- Presence of intercurrent illness or any condition (i.e. severe vomiting and dehydration) which in the judgement of the Investigator would place the patient at undue risk or interfere with the study results;

- Hypoglycaemia (blood glucose levels < 2.2 mmol/L or < 40 mg/dL);

- Splenectomy;

- Pregnant or lactating women. During the study period (Day 0- Day 42), fertile women who are sexually active must use an adequate birth control method. They should utilize oral or patch contraceptives, contraceptive implant or depot injection or an intrauterine device from at least one month before screening and during the whole study period. In all the other cases they have to agree to remain inactive or use condoms with a spermicidal agent during the study period;

- Presence of jaundice;

- Known renal impairment (serum creatinine > 2X the upper limit of the hospital laboratory reference range);

- Known liver insufficiency (AST and/or ALT > 3X the upper limit of the hospital laboratory reference range);

- Relevant anaemia (Hb< 8 g/dL).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Eurartesim tablets
dosage bands: 24 to <36 kg body weight: 2 tablets a day for three consecutive days 36 to <75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days

Locations

Country Name City State
France Hôpital St André-CHU, Médecine interne et Maladies tropicales Bordeaux Cedex
Germany Medizinische Klinik mit Schwerpunkt Infektiologie, Charite/Campus Virchow-Klinikum Berlin
Germany Department of Infectious Diseases & Tropical Medicine, University of Munich Munich
Israel 15. The Center for Geographic Medicine and Tropical Diseases, Department of Medicine C - The Chaim Sheba Medical Center Tel Hashomer
Italy Clinica di Malattie Infettive e Tropicali, Universitá di Brescia Brescia
Italy Azienda ospedaliera Luigi Sacco Milano
Italy Azienda Ospedaliera Arcispedale S. Maria Nuova IRCCS - Dip. Medicina Interna e Spec. Mediche Reggio Emilia
Italy Centro di Malattie Tropicali - INMI Spallanzani Roma
Netherlands Dep. Infectious Disease, Section Travel Medicine, Leiden University Medical Centre Leiden
Spain CRESIB-Hospital Clinic, Barcelona Barcelona
Spain Hospital Vall d'Hebron, Barcelona Barcelona
Switzerland Medical and Diagnostic Service Department, Swiss Tropical and Public Health Institute Basel
Switzerland Bern University Hospital Bern

Sponsors (1)

Lead Sponsor Collaborator
Alfasigma S.p.A.

Countries where clinical trial is conducted

France,  Germany,  Israel,  Italy,  Netherlands,  Spain,  Switzerland, 

References & Publications (3)

Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007 Apr 15;44(8):1067-74. Epub 2007 Mar 5. — View Citation

Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007 Mar 3;369(9563):757-765. doi: 10.1016/S0140-6736(07)60160-3. — View Citation

Sinclair D, Gogtay N, Brand F, Olliaro P. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008492. doi: 10.1002/14651858.CD008492.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;10:CD008492. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Uncorrected adequate clinical and parasitological response (ACPR) The uncorrected ACPR will be considered met for all those patients that are not presenting parasitaemia and fever at day 21 follow-up visit. 21 days after the start of treatment
Secondary Proportion of aparasitaemic patients to evaluate efficacy of the treatment to clear blood from parasites at day 1, 2, 3, 7, 21, 42
Secondary Proportion of afebrile patients to evaluate the efficacy of eurartesim in reducing fever caused by malaria at day 1, 2, 3, 7, 21, 42
Secondary uncorrected ACPR at day 42
Secondary Number of Patients with Serious and Non-Serious Adverse Events up to 42 days from starting of treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05096702 - Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
Recruiting NCT05540470 - Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield N/A
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT03307369 - A Retrospective Study of Severe Plasmodium Vivax
Completed NCT01213966 - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Phase 2
Completed NCT00811096 - Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Phase 2
Terminated NCT03337152 - Assessing a Risk Model for G6PD Deficiency Phase 4
Completed NCT05753150 - Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
Completed NCT02751294 - A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed NCT03377296 - Study of Controlled Human Plasmodium Vivax Infection N/A
Completed NCT00486694 - Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria Phase 2
Recruiting NCT05788094 - ACT vs CQ With Tafenoquine for P. Vivax Mono-infection Phase 4
Not yet recruiting NCT05690841 - FocaL Mass Drug Administration for Vivax Malaria Elimination Phase 3
Not yet recruiting NCT04739917 - Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers Phase 2
Completed NCT03208907 - DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil Phase 3
Completed NCT02184637 - A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate Phase 1
Completed NCT01928914 - Tafenoquine Thorough QTc Study in Healthy Subjects Phase 1
Completed NCT00157885 - A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia. N/A
Completed NCT01081847 - Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants Phase 1